EMA sets forward proposals to revise guidance on first-in-human clinical trials
The European Medicines Agency (EMA), in cooperation with the European Commission and the Member States of the European Union (EU), has proposed changes to the current guidance on first-in-human clinical trials. These changes are designed to hopefully further improve strategies which help to identify and mitigate risks to trial participants.
To read more about this, please click here.
